Growth compensatory role of sulindac sulfide-induced thrombospondin-1 linked with ERK1/2 and RhoA GTPase signaling pathways

Life Sciences

Volumn 82, Issue 11-12, 2008, Pages 591-599

  Moon, Yuseok ^a   Kim, Jeung Il ^b   Yang, Hyun ^a   Eling, Thomas E ^c  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University Hospital   (South Korea)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

ERK1 2; RhoA; Thrombospondin 1

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GUANOSINE TRIPHOSPHATASE; INDOMETACIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NONSTEROID ANTIINFLAMMATORY AGENT; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SULINDAC SULFIDE; THROMBOSPONDIN 1;

ARTICLE; CELL GROWTH; CELL INVASION; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; MITOGENESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION; HUMANS; IBUPROFEN; INDOMETHACIN; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; SULINDAC; THROMBOSPONDIN 1;

EID: 39649113741     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.11.030     Document Type: Article

References (36)

1. Adams J.C. Thrombospondins: multifunctional regulators of cell interactions. Annual Review Cell and Developmental Biology 17 (2001) 25-51
2. Adams J.C., and Lawler J. The thrombospondins. International Journal of Biochemistry and Cell Biology 36 (2004) 961-968
3. Anilkumar N., Annis D.S., Mosher D.F., and Adams J.C. Trimeric assembly of the C-terminal region of thrombospondin-1 or thrombospondin-2 is necessary for cell spreading and fascin spike organisation. Journal of Cell Science 115 (2002) 2357-2366
4. Baek S.J., Wilson L.C., Lee C.H., and Eling T.E. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. Journal of Pharmacology and Experimental Therapeutics 301 (2002) 1126-1131
5. Braddock M. The transcription factor Egr-1: a potential drug in wound healing and tissue repair. Annals of Medicine 33 (2001) 313-318
6. Clezardin P., Frappart L., Clerget M., Pechoux C., and Delmas P.D. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Research 53 (1993) 1421-1430
7. Connolly E.M., Harmey J.H., O'Grady T., Foley D., Roche-Nagle G., Kay E., and Bouchier-Hayes D.J. Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. British Journal of Cancer 87 (2002) 231-237
8. Davies N.M., and Watson M.S. Clinical pharmacokinetics of sulindac. A dynamic old drug. Clinical Pharmacokinetics 32 (1997) 437-459
9. Desai L.P., Aryal A.M., Ceacareanu B., Hassid A., and Waters C.M. RhoA and Rac1 are both required for efficient wound closure of airway epithelial cells. American Journal of Physiology. Lung Cellular and Molecular Physiology 287 (2004) L1134-L1144
10. DiPietro L.A., Nissen N.N., Gamelli R.L., Koch A.E., Pyle J.M., and Polverini P.J. Thrombospondin 1 synthesis and function in wound repair. American Journal of Pathology 148 (1996) 1851-1860
11. Duggan D.E., Hooke K.F., and Hwang S.S. Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation. Drug Metabolism and Disposition 8 (1980) 241-246
12. Guo H., Ray R.M., and Johnson L.R. RhoA stimulates IEC-6 cell proliferation by increasing polyamine-dependent Cdk2 activity. American Journal of Physiology-Gastrointestinal and Liver Physiology 285 (2003) G704-G713
13. Gutierrez L.S., Suckow M., Lawler J., Ploplis V.A., and Castellino F.J. Thrombospondin 1 - a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model. Carcinogenesis 24 (2003) 199-207
14. Horiuchi A., Imai T., Wang C., Ohira S., Feng Y., Nikaido T., and Konishi I. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Laboratory Investigation 83 (2003) 861-870
15. Ichii T., Koyama H., Tanaka S., Shioi A., Okuno Y., Otani S., and Nishizawa Y. Thrombospondin-1 mediates smooth muscle cell proliferation induced by interaction with human platelets. Arteriosclerosis, Thrombosis and Vascular Biology 22 (2002) 1286-1292
16. Kim J., Kim C., Kim T.S., Bang S.I., Yang Y., Park H., and Cho D. IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway. Biochemical Biophysical Research Communications 344 (2006) 1284-1289
17. Kohno M., and Pouyssegur J. Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs. Progress in Cell Cycle Research 5 (2003) 219-224
18. Liu C., Rangnekar V.M., Adamson E., and Mercola D. Suppression of growth and transformation and induction of apoptosis by EGR-1. Cancer Gene Therapy 5 (1998) 3-28
19. Maier T.J., Janssen A., Schmidt R., Geisslinger G., and Grosch S. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB Journal 19 (2005) 1353-1355
20. Maile L.A., and Clemmons D.R. Integrin-associated protein binding domain of thrombospondin-1 enhances insulin-like growth factor-I receptor signaling in vascular smooth muscle cells. Circulation Research 93 (2003) 925-931
21. Majack R.A., Mildbrandt J., and Dixit V.M. Induction of thrombospondin messenger RNA levels occurs as an immediate primary response to platelet-derived growth factor. Journal of Biological Chemistry 262 (1987) 8821-8825
22. McGillicuddy F.C., O'Toole D., Hickey J.A., Gallagher W.M., Dawson K.A., and Keenan A.K. TGF-beta1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells. Vascular Pharmacology 44 (2006) 469-475
23. Moon Y., Bottone Jr. F.G., McEntee M.F., and Eling T.E. Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1. Molecular Cancer Therapeutics 4 (2005) 1551-1558
24. Moon Y., Yang H., and Kim Y.B. Up-regulation of early growth response gene 1 (EGR-1) via ERK1/2 signals attenuates sulindac sulfide-mediated cytotoxicity in the human intestinal epithelial cells. Toxicology and Applied Pharmacology 223 (2007) 155-163
25. Nakagawa T., Lan H.Y., Glushakova O., Zhu H.J., Kang D.H., Schreiner G.F., Bottinger E.P., Johnson R.J., and Sautin Y.Y. Role of ERK1/2 and p38 mitogen-activated protein kinases in the regulation of thrombospondin-1 by TGF-beta1 in rat proximal tubular cells and mouse fibroblasts. Journal of American Society of Nephrology 16 (2005) 899-904
26. Rao C.V., Rivenson A., Simi B., Zang E., Kelloff G., Steele V., and Reddy B.S. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Research 55 (1995) 1464-1472
27. Reddy B.S., Rao C.V., and Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Research 56 (1996) 4566-4569
28. Roberts D.D. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB Journal 10 (1996) 1183-1191
29. Rolfe B.E., Worth N.F., World C.J., Campbell J.H., and Campbell G.R. Rho and vascular disease. Atherosclerosis 183 (2005) 1-16
30. Sun Y., and Sinicrope F.A. Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells. Molecular Cancer Therapeutics 4 (2005) 51-59
31. Tarnawski A.S. Cellular and molecular mechanisms of gastrointestinal ulcer healing. Digestive Diseases and Sciences 50 Supplement 1 (2005) S24-S33
32. Tegeder I., Pfeilschifter J., and Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB Journal 15 (2001) 2057-2072
33. Yamaguchi M., Sugio K., Ondo K., Yano T., and Sugimachi K. Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer. Lung Cancer 36 (2002) 143-150
34. Yoshida S., Amano H., Hayashi I., Kitasato H., Kamata M., Inukai M., Yoshimura H., and Majima M. COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Laboratory Investigation 83 (2003) 1385-1394
35. Zhang X., Morham S.G., Langenbach R., and Young D.A. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. Journal of Experimental Medicine 190 (1999) 451-459
36. Zhou Y., Su Y., Li B., Liu F., Ryder J.W., Wu X., Gonzalez-DeWhitt P.A., Gelfanova V., Hale J.E., May P.C., Paul S.M., and Ni B. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 302 (2003) 1215-1217